HYPD vs IFRX

Hyperion DeFi, Inc. vs InflaRx N.V. — Valuation Comparison 2026

HYPD

Pharmaceutical Preparations
Hyperion DeFi, Inc.
Quality
5.1
out of 10
Value Trap
20
SAFE
Price
$3.50
Last close
Models
11/13
Active
VS

IFRX

Pharmaceutical Preparations
InflaRx N.V.
Quality
1.8
out of 10
Value Trap
Price
$2.40
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType HYPD Fair ValueHYPD Upside IFRX Fair ValueIFRX Upside
Bayesian DCF Intrinsic $1.10 -68.6% $0.64 -73.3%
Earnings Power Value Intrinsic $1.61 -61.4%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $4.03 +15.2% $0.89 -63.0%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for HYPD vs IFRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HYPD vs IFRX — Which Stock Is More Undervalued?

HYPD scores higher with a 5.1/10 quality rating vs IFRX's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Hyperion DeFi, Inc. (HYPD) and InflaRx N.V. (IFRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HYPD currently trades at $3.50 with a QOC of 5.1/10, while IFRX trades at $2.40 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).